About clearmind medicine inc - CMND
Clearmind Medicine, Inc. is a psychedelic pharmaceutical biotech company. It focuses on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and underserved health problems, including alcohol use disorder. Its primary objective is to research and develop psychedelic-based compounds and attempt to commercialize it as regulated medicines, foods, or supplements. The company was founded on July 18, 2017 and is headquartered in Vancouver, Canada.
CMND At a Glance
Clearmind Medicine, Inc.
1220 West 6th Avenue
Vancouver, British Columbia V6H 1A5
| Phone | 1-973-536-1016 | Revenue | 0.00 | |
| Industry | Other Metals/Minerals | Net Income | -3,856,983.00 | |
| Sector | Non-Energy Minerals | Employees | N/A | |
| Fiscal Year-end | 10 / 2026 | |||
| View SEC Filings |
CMND Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | N/A |
| Price to Book Ratio | 4.218 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -0.042 |
| Enterprise Value to Sales | N/A |
| Total Debt to Enterprise Value | 7.49 |
CMND Efficiency
| Revenue/Employee | N/A |
| Income Per Employee | N/A |
| Receivables Turnover | N/A |
| Total Asset Turnover | N/A |
CMND Liquidity
| Current Ratio | 1.216 |
| Quick Ratio | 1.216 |
| Cash Ratio | 1.142 |
CMND Profitability
| Gross Margin | N/A |
| Operating Margin | N/A |
| Pretax Margin | N/A |
| Net Margin | N/A |
| Return on Assets | -57.832 |
| Return on Equity | -179.388 |
| Return on Total Capital | -129.801 |
| Return on Invested Capital | -178.706 |
CMND Capital Structure
| Total Debt to Total Equity | 149.159 |
| Total Debt to Total Capital | 59.865 |
| Total Debt to Total Assets | 29.243 |
| Long-Term Debt to Equity | N/A |
| Long-Term Debt to Total Capital | N/A |